Clinical & Experimental Metastasis最新文献

筛选
英文 中文
Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker. Nectin-4在原发性唾液腺癌症和相应的淋巴结转移中频繁表达,是一种重要的治疗相关生物标志物。
IF 4 3区 医学
Clinical & Experimental Metastasis Pub Date : 2023-10-01 Epub Date: 2023-07-22 DOI: 10.1007/s10585-023-10222-w
Marcel Mayer, Lisa Nachtsheim, Johanna Prinz, Sami Shabli, Malte Suchan, Jens Peter Klußmann, Alexander Quaas, Christoph Arolt, Philipp Wolber
{"title":"Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker.","authors":"Marcel Mayer,&nbsp;Lisa Nachtsheim,&nbsp;Johanna Prinz,&nbsp;Sami Shabli,&nbsp;Malte Suchan,&nbsp;Jens Peter Klußmann,&nbsp;Alexander Quaas,&nbsp;Christoph Arolt,&nbsp;Philipp Wolber","doi":"10.1007/s10585-023-10222-w","DOIUrl":"10.1007/s10585-023-10222-w","url":null,"abstract":"<p><p>Many locally advanced and metastatic salivary gland carcinomas (SGC) lack therapeutic targets. Enfortumab vedotin, an antibody-drug conjugate binding to Nectin-4, recently gained FDA approval for third-line urothelial carcinoma. Therefore, the aim of this study was to assess the expression of Nectin-4 in primary SGC and corresponding lymph node metastases and to correlate it with clinicopathological data. Immunohistochemical staining for Nectin-4 was performed for patients who had undergone surgery with curative intent for primary SGC of the parotid or submandibular gland in a tertiary referral center between 1990 and 2019. One hundred twenty-two primary SGC and twenty corresponding lymph node metastases were included. Nectin-4 was expressed in 80.3% of primary SGC with a mean Histo(H-)score of 61.2 and in 90.0% of lymph node metastases with a mean H-score of 75.6. A moderate or high Nectin-4 expression was found in 25.9% of salivary duct carcinomas (SaDu) and in 30.7% of adenoid cystic carcinomas (ACC). SaDu patients with a lower T-stage (p = 0.04), no loco-regional lymph node metastases (p = 0.049), no vascular invasion (p = 0.04), and no perineural spread (p = 0.03) showed a significantly higher mean Nectin-4 H-score. There was a statistical tendency towards a more favorable disease-free survival among SaDu patients with a higher Nectin-4 expression (p = 0.09). Nectin-4 is expressed in SGC and therefore represents a potential therapeutic target, especially in entities with a high rate of local recurrence and metastatic spread such as SaDu and ACC.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"40 5","pages":"395-405"},"PeriodicalIF":4.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10603208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world. 现实世界中广泛期小细胞肺癌癌症经免疫治疗后胸部放射治疗的有效性和安全性。
IF 4 3区 医学
Clinical & Experimental Metastasis Pub Date : 2023-10-01 Epub Date: 2023-08-16 DOI: 10.1007/s10585-023-10227-5
Min Fang, Le Wang, Qing Gu, Huiwen Wu, Xianghui Du, Xiaojing Lai
{"title":"Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world.","authors":"Min Fang,&nbsp;Le Wang,&nbsp;Qing Gu,&nbsp;Huiwen Wu,&nbsp;Xianghui Du,&nbsp;Xiaojing Lai","doi":"10.1007/s10585-023-10227-5","DOIUrl":"10.1007/s10585-023-10227-5","url":null,"abstract":"<p><p>The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive-stage small lung cancer (ES-SCLC). The CREST trial reported consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for ES-SCLC with intrathoracic residual after chemotherapy. In this study, patients with ES-SCLC who received immunotherapy were assigned to receive either TRT or no TRT. TRT significantly improved progression-free survival (PFS), local recurrence-free survival (LRFS) and OS with well tolerated toxicity. Further sub-cohort analysis, TRT significantly improved LRFS in patients with oligo-metastasis and without liver metastasis.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"40 5","pages":"423-429"},"PeriodicalIF":4.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10210123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Correction: Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival. 更正:长链ω-3多不饱和脂肪酸可减少乳腺肿瘤的生长、多器官转移并提高生存率。
IF 4 3区 医学
Clinical & Experimental Metastasis Pub Date : 2023-10-01 DOI: 10.1007/s10585-023-10226-6
Saraswoti Khadge, Geoffrey M Thiele, John Graham Sharp, Timothy R McGuire, Lynell W Klassen, Paul N Black, Concetta C DiRusso, Leah Cook, James E Talmadge
{"title":"Correction: Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival.","authors":"Saraswoti Khadge,&nbsp;Geoffrey M Thiele,&nbsp;John Graham Sharp,&nbsp;Timothy R McGuire,&nbsp;Lynell W Klassen,&nbsp;Paul N Black,&nbsp;Concetta C DiRusso,&nbsp;Leah Cook,&nbsp;James E Talmadge","doi":"10.1007/s10585-023-10226-6","DOIUrl":"10.1007/s10585-023-10226-6","url":null,"abstract":"","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"40 5","pages":"441"},"PeriodicalIF":4.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10197713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between primary tumor characteristics and histopathological growth pattern of liver metastases in colorectal cancer. 癌症原发性肿瘤特征与肝转移组织病理学生长模式的关系。
IF 4 3区 医学
Clinical & Experimental Metastasis Pub Date : 2023-10-01 Epub Date: 2023-07-15 DOI: 10.1007/s10585-023-10221-x
Ali Bohlok, Camille Tonneau, Sophie Vankerckhove, Ligia Craciun, Valerio Lucidi, Fikri Bouazza, Alain Hendlisz, Jean Luc Van Laethem, Denis Larsimont, Peter Vermeulen, Vincent Donckier, Pieter Demetter
{"title":"Association between primary tumor characteristics and histopathological growth pattern of liver metastases in colorectal cancer.","authors":"Ali Bohlok,&nbsp;Camille Tonneau,&nbsp;Sophie Vankerckhove,&nbsp;Ligia Craciun,&nbsp;Valerio Lucidi,&nbsp;Fikri Bouazza,&nbsp;Alain Hendlisz,&nbsp;Jean Luc Van Laethem,&nbsp;Denis Larsimont,&nbsp;Peter Vermeulen,&nbsp;Vincent Donckier,&nbsp;Pieter Demetter","doi":"10.1007/s10585-023-10221-x","DOIUrl":"10.1007/s10585-023-10221-x","url":null,"abstract":"<p><strong>Introduction: </strong>The microarchitecture of liver metastases (LMs), or histopathological growth pattern (HGP), has been demonstrated to be a significant prognostic factor in patients undergoing resection of colorectal liver metastases (CRLMs). Currently, however, HGP can be only determined on the operative specimen. Therefore, the development of new tools to predict the HGP of CRLMs before surgery and to understand the mechanisms that drive these patterns is important for improving individualization of therapeutic management. In this study, we analyzed data from a retrospective series of patients who underwent surgery for CRLMs to compare primary tumor characteristics, including markers of local aggressiveness and migratory capacity, and HGP of liver metastases.</p><p><strong>Methods: </strong>Data from a retrospective series of 167 patients who underwent curative-intent resection of CRLMs and in whom pathological samples from both primary tumor and liver metastases were available were reviewed. At the primary tumor level, KRAS mutational status, grade of differentiation, and tumor budding were assessed. HGP was scored in each resected CRLM, according to consensus guidelines, and classified as desmoplastic (dHGP) or non-desmoplastic (non-dHGP). Associations between primary tumor characteristics and HGP of CRLMs were evaluated using a binary logistic regression model. Overall survival and disease-free survival were evaluated using Kaplan-Meier and multivariable Cox regression analyses.</p><p><strong>Results: </strong>CRLMs were classified as dHGP in 36% of the patients and as non-dHGP in 64%. Higher rates of moderately or poorly differentiated primary tumors were observed in the non-dHGP CRLM group (80%), as compared with the dHGP group (60%) (OR = 3.6; 95%CI: 1.6-7.05; p = 0.001). Higher rates of tumor budding were observed in the non-dHGP CRLM group, with a median tumor budding value of 4 as compared with 2.5 in the dHGP group (p = 0.042). In the entire series, 5-year overall and disease-free survival were 43% and 32.5%, respectively. The non-dHGP CRLM group had worse post-hepatectomy survival, with 5-year overall and disease-free survival of 32.2% and 24.6%, respectively, as compared with 60.8% and 45.9%, respectively, for the dHGP group (p = 0.02).</p><p><strong>Conclusion: </strong>Colorectal tumors with moderate or poor differentiation and those with high tumor budding are more frequently associated with CRLMs with a non-dHGP. This suggests that primary tumor characteristics of local aggressiveness and migratory capacity could preferentially promote the development of CRLMs with an infiltrating pattern and that these parameters should be considered as part of new scores for predicting HGP before surgery. This finding may stimulate new lines of research for more individualized therapeutic decision in patients with CRLM candidate to surgery.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"40 5","pages":"431-440"},"PeriodicalIF":4.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10273042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic impact of EGFR/ALK alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy. EGFR/ALK改变对全脑放射治疗肺腺癌软脑膜转移的预后影响。
IF 4 3区 医学
Clinical & Experimental Metastasis Pub Date : 2023-10-01 Epub Date: 2023-07-19 DOI: 10.1007/s10585-023-10225-7
Hidekazu Oyoshi, Hidenari Hirata, Yasuhiro Hirano, Sadamoto Zenda, Yuzheng Zhou, Kento Tomizawa, Takeshi Fujisawa, Masaki Nakamura, Hidehiro Hojo, Atsushi Motegi, Shun-Ichiro Kageyama, Yoshitaka Zenke, Koichi Goto, Shunichi Ishihara, Shinji Naganawa, Tetsuo Akimoto
{"title":"Prognostic impact of EGFR/ALK alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy.","authors":"Hidekazu Oyoshi,&nbsp;Hidenari Hirata,&nbsp;Yasuhiro Hirano,&nbsp;Sadamoto Zenda,&nbsp;Yuzheng Zhou,&nbsp;Kento Tomizawa,&nbsp;Takeshi Fujisawa,&nbsp;Masaki Nakamura,&nbsp;Hidehiro Hojo,&nbsp;Atsushi Motegi,&nbsp;Shun-Ichiro Kageyama,&nbsp;Yoshitaka Zenke,&nbsp;Koichi Goto,&nbsp;Shunichi Ishihara,&nbsp;Shinji Naganawa,&nbsp;Tetsuo Akimoto","doi":"10.1007/s10585-023-10225-7","DOIUrl":"10.1007/s10585-023-10225-7","url":null,"abstract":"<p><p>The prognosis and prognostic factors of patients receiving whole-brain radiotherapy (WBRT) for leptomeningeal metastasis (LM) from lung adenocarcinoma have not been established. Particularly, the impact of EGFR mutations and ALK rearrangements on survival remains unclear. This retrospective study evaluated the prognosis and prognostic factors of patients receiving WBRT for LM. We evaluated overall survival (OS) from WBRT initiation and clinical variables in 80 consecutive patients receiving WBRT for LM from lung adenocarcinoma at our institution between June 2013 and June 2021. After a median follow-up of 5.2 (range 0.5-56.5) months, the median OS was 6.2 months (95% CI 4.4-12.4). Of the 80 patients, 51 were classified as EGFR/ALK mutant (EGFR: 44; ALK: 6; both: 1) and 29 as wild-type. The median OS was 10.4 (95% CI 5.9-20.9) versus 3.8 (95% CI 2.5-7.7) months in the EGFR/ALK-mutant versus wild-type patients (HR = 0.49, P = 0.0063). Multivariate analysis indicated that EGFR/ALK alterations (HR = 0.54, P = 0.021) and Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1 (HR = 0.25, P < 0.001) were independent factors associated with favorable OS. Among the patients who underwent brain MRI before and after WBRT, intracranial progression-free survival was longer in the 26 EGFR/ALK-mutant than 13 wild-type patients (HR = 0.31, P = 0.0039). Although the prognosis of patients receiving WBRT for LM remains poor, EGFR/ALK alterations and good ECOG PS may positively impact OS in those eligible for WBRT.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"40 5","pages":"407-413"},"PeriodicalIF":4.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10216005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
'Sandwich treatment' for posterior fossa brain metastases with volume larger than 4cm3: a multicentric retrospective study. 体积大于4cm3的后颅窝脑转移瘤的“三明治治疗”:一项多中心回顾性研究。
IF 4 3区 医学
Clinical & Experimental Metastasis Pub Date : 2023-10-01 Epub Date: 2023-07-13 DOI: 10.1007/s10585-023-10220-y
Zheng Wang, Haining Chen, Qun Chen, Yucun Zhu, Min Li, Zhou Jia
{"title":"'Sandwich treatment' for posterior fossa brain metastases with volume larger than 4cm<sup>3</sup>: a multicentric retrospective study.","authors":"Zheng Wang,&nbsp;Haining Chen,&nbsp;Qun Chen,&nbsp;Yucun Zhu,&nbsp;Min Li,&nbsp;Zhou Jia","doi":"10.1007/s10585-023-10220-y","DOIUrl":"10.1007/s10585-023-10220-y","url":null,"abstract":"<p><p>Single stereotactic radiosurgery (SRS) for posterior fossa brain metastases (BM) larger than 4cm<sup>3</sup> is dangerous. 'Sandwich treatment' strategy was developed for these BMs. The strategy was one week treatment course which includes 2-stage SRS and using Bevacizumab once during SRS gap. Patients from four gamma knife center were retrospectively analyzed. The changes of tumor and peri-tumor edema volume were studied. The Dizziness Handicap Inventory (DHI) Vomiting Score (VS) and Glasgow Coma Scale (GCS) were used to evaluate patients' clinical symptom changes. Karnofsky performance scale (KPS) and Barthel Index (BI) were used to evaluate patients' overall fitness status and physical activity rehabilitation. Tumor local control (TLC) and patients' overall survival (OS) rate were also calculated. Forty patients with 45 LBMs received 'Sandwich treatment'. The mean edema volume reduced remarkably at the course of therapy and 3 months later (P < 0.01). The mean tumor volume greatly decreased 3 months later (P < 0.01). Patients' clinical symptoms that reflected by median score of DHI, VS, GCS were improved dramatically at the course of therapy and 3 months later (P < 0.01). Similar changes happened in median score of KPS and BI that reflected patients' overall fitness status and physical activity rehabilitation (P < 0.01). Patients' median OS was 14.3 months, with 95.4%, 76.2%, and 26.3% survival rate at 6, 12, 24 months. The TLC rate at 6, 12, 24 months was 97.5%, 86.0% and 62.2%.The 'Sandwich treatment' is safe and effective for patients with LBM over 4cm<sup>3</sup> in the posterior fossa. The strategy could quickly improve patients' symptoms, well control tumor growth, prolong patient's OS, and has controllable side effects.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"40 5","pages":"415-422"},"PeriodicalIF":4.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10220668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary tumor resection or systemic treatment as palliative treatment for patients with isolated synchronous colorectal cancer peritoneal metastases in a nationwide cohort study. 在一项全国性队列研究中,原发性肿瘤切除或全身治疗作为孤立的同步结直肠癌腹膜转移患者的姑息性治疗。
IF 4 3区 医学
Clinical & Experimental Metastasis Pub Date : 2023-08-01 DOI: 10.1007/s10585-023-10212-y
Anouk Rijken, Vincent C J van de Vlasakker, Geert A Simkens, Koen P Rovers, Felice N van Erning, Miriam Koopman, Cornelis Verhoef, Johannes H W de Wilt, Ignace H J T de Hingh
{"title":"Primary tumor resection or systemic treatment as palliative treatment for patients with isolated synchronous colorectal cancer peritoneal metastases in a nationwide cohort study.","authors":"Anouk Rijken,&nbsp;Vincent C J van de Vlasakker,&nbsp;Geert A Simkens,&nbsp;Koen P Rovers,&nbsp;Felice N van Erning,&nbsp;Miriam Koopman,&nbsp;Cornelis Verhoef,&nbsp;Johannes H W de Wilt,&nbsp;Ignace H J T de Hingh","doi":"10.1007/s10585-023-10212-y","DOIUrl":"https://doi.org/10.1007/s10585-023-10212-y","url":null,"abstract":"<p><p>Limited data are available to guide the decision-making process for clinicians and their patients regarding palliative treatment options for patients with isolated synchronous colorectal cancer peritoneal metastases (CRC-PM). Therefore, the aim of this study is to analyze the outcome of the different palliative treatments for these patients. All patients diagnosed with isolated synchronous CRC-PM between 2009 and 2020 (Netherlands Cancer Registry) who underwent palliative treatment were included. Patients who underwent emergency surgery or curative intent treatment were excluded. Patients were categorized into upfront palliative primary tumor resection (with or without additional systemic treatment) or palliative systemic treatment only. Overall survival (OS) was compared between both groups and multivariable cox regression analysis was performed. Of 1031 included patients, 364 (35%) patients underwent primary tumor resection and 667 (65%) patients received systemic treatment only. Sixty-day mortality was 9% in the primary tumor resection group and 5% in the systemic treatment group (P = 0.007). OS was 13.8 months in the primary tumor resection group and 10.3 months in the systemic treatment group (P < 0.001). Multivariable analysis showed that primary tumor resection was associated with improved OS (HR 0.68; 95%CI 0.57-0.81; P < 0.001). Palliative primary tumor resection appeared to be associated with improved survival compared to palliative systemic treatment alone in patients with isolated synchronous CRC-PM despite a higher 60-day mortality. This finding must be interpreted with care as residual bias probably played a significant role. Nevertheless, this option may be considered in the decision-making process by clinicians and their patients.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"40 4","pages":"289-298"},"PeriodicalIF":4.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9784327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LITAF inhibits colorectal cancer stemness and metastatic behavior by regulating FOXO1-mediated SIRT1 expression. LITAF通过调节fox01介导的SIRT1表达抑制结直肠癌的干细胞和转移行为。
IF 4 3区 医学
Clinical & Experimental Metastasis Pub Date : 2023-08-01 DOI: 10.1007/s10585-023-10213-x
Jiao Guan, Zheng-Yun Zhang, Jian-Hua Sun, Xin-Ping Wang, Zun-Qiang Zhou, Lei Qin
{"title":"LITAF inhibits colorectal cancer stemness and metastatic behavior by regulating FOXO1-mediated SIRT1 expression.","authors":"Jiao Guan,&nbsp;Zheng-Yun Zhang,&nbsp;Jian-Hua Sun,&nbsp;Xin-Ping Wang,&nbsp;Zun-Qiang Zhou,&nbsp;Lei Qin","doi":"10.1007/s10585-023-10213-x","DOIUrl":"https://doi.org/10.1007/s10585-023-10213-x","url":null,"abstract":"<p><p>Lipopolysaccharide-induced tumor necrosis factor alpha factor (LITAF) is a transcription factor that activates the transcription of TNF-α and regulates the inflammatory response. LITAF has been found to have potential anti-cancer effects of in several tumors. However, the role of LITAF in colorectal cancer (CRC) remains unclear. Through a comprehensive pan-cancer analysis of the Cancer Genome Atlas (TCGA), LITAF was identified as a differentially downregulated gene in CRC. We hypothesized that LITAF may participate in the modulation of CRC progression. The present study was aimed to investigate the expression profile of LITAF in CRC and its effect on metastatic behavior and stemness as well as the underlying molecular mechanism. The expression profile of LITAF in CRC, and its relationship with the prognosis of CRC were explored using public databases. LITAF expression was detected by quantitative real-time PCR (qRT-PCR), western blot, and immunohistochemistry. Furthermore, the effects of overexpression or knockdown of LITAF on cell proliferation, apoptosis, migration, invasion, and stemness of CRC cells were investigated in vitro. The regulatory effect of LITAF on forkhead Box O 1 (FOXO1)-sirtuin 1 (SIRT1) signaling axis was also explored. In addition, a xenograft mouse model was used to investigate the in-vivo role of LITAF. LITAF was downregulated in tumor tissues and its expression was associated with the prognosis, pathological stage and liver metastasis. In-vitro experiments confirmed that LITAF inhibited tumor cell proliferation, migration, invasion and stemness, and induced cell apoptosis. In vivo experiments demonstrated that LITAF inhibited the tumorigenicity and liver metastasis in tumor-bearing mice. Additionally, LITAF promoted FOXO1-mediated SIRT1 inhibition, thus regulating cancer stemness and malignant phenotypes. LITAF was silenced in CRC and it participated in the progression of CRC by inhibiting CRC cell stemness, and malignant phenotypes. Therefore, LITAF may serve as a novel biomarker of CRC prognosis.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"40 4","pages":"309-320"},"PeriodicalIF":4.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9794836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Platycodin D represses β-catenin to suppress metastasis of cetuximab-treated KRAS wild-type colorectal cancer cells. Platycodin D抑制β-catenin抑制西妥昔单抗治疗KRAS野生型结直肠癌细胞的转移。
IF 4 3区 医学
Clinical & Experimental Metastasis Pub Date : 2023-08-01 DOI: 10.1007/s10585-023-10218-6
Yongming Lv, Wenhong Wang, Yanfei Liu, Ben Yi, Tianhao Chu, Zhiqiang Feng, Jun Liu, Xuehua Wan, Yijia Wang
{"title":"Platycodin D represses β-catenin to suppress metastasis of cetuximab-treated KRAS wild-type colorectal cancer cells.","authors":"Yongming Lv,&nbsp;Wenhong Wang,&nbsp;Yanfei Liu,&nbsp;Ben Yi,&nbsp;Tianhao Chu,&nbsp;Zhiqiang Feng,&nbsp;Jun Liu,&nbsp;Xuehua Wan,&nbsp;Yijia Wang","doi":"10.1007/s10585-023-10218-6","DOIUrl":"https://doi.org/10.1007/s10585-023-10218-6","url":null,"abstract":"<p><p>Cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, is extensively used for clinical therapy in KRAS wild-type colorectal cancer (CRC) patients. However, some patients still cannot get benefit from the therapy, because metastasis and resistance occur frequently after cetuximab treatment. New adjunctive therapy is urgently needed to suppress metastasis of cetuximab-treated CRC cells. In this study, we used two KRAS wild-type CRC cells, HT29 and CaCo2, to investigate whether platycodin D, a triterpenoid saponin isolated from Chinese medicinal herb Platycodon grandifloras, is able to suppress the metastasis of cetuximab-treated CRC. Label-free quantitative proteomics analyses showed that platycodin D but not cetuximab significantly inhibited expression of β-catenin in both CRC cells, and suggested that platycodin D counteracted the inhibition effect of cetuximab on cell adherence and functioned in repressing cell migration and invasion. Western blot results showed that single platycodin D treatment or combined platycodin D and cetuximab enhanced inhibition effects on expressions of key genes in Wnt/β-catenin signaling pathway, including β-catenin, c-Myc, Cyclin D1 and MMP-7, compared to single cetuximab treatment. Scratch wound-healing and transwell assays showed that platycodin D combined with cetuximab suppressed migration and invasion of CRC cells, respectively. Pulmonary metastasis model of HT29 and CaCo2 in nu/nu nude mice consistently showed that combined treatment using platycodin D and cetuximab inhibited metastasis significantly in vivo. Our findings provide a potential strategy to inhibit CRC metastasis during cetuximab therapy by addition of platycodin D.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"40 4","pages":"339-356"},"PeriodicalIF":4.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9854281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EGFL6 promotes bone metastasis of lung adenocarcinoma by increasing cancer cell malignancy and bone resorption. EGFL6通过增加癌细胞恶性程度和骨吸收促进肺腺癌骨转移。
IF 4 3区 医学
Clinical & Experimental Metastasis Pub Date : 2023-08-01 DOI: 10.1007/s10585-023-10219-5
Xiaoting Song, Xu Cheng, Xiangang Jin, Shengyu Ruan, Xianquan Xu, Feng Lu, Xinhui Wu, Fangying Lu, Mingxuan Feng, Liwei Zhang, Renshan Ge, Haixiao Chen, Zhenghua Hong, Dun Hong
{"title":"EGFL6 promotes bone metastasis of lung adenocarcinoma by increasing cancer cell malignancy and bone resorption.","authors":"Xiaoting Song,&nbsp;Xu Cheng,&nbsp;Xiangang Jin,&nbsp;Shengyu Ruan,&nbsp;Xianquan Xu,&nbsp;Feng Lu,&nbsp;Xinhui Wu,&nbsp;Fangying Lu,&nbsp;Mingxuan Feng,&nbsp;Liwei Zhang,&nbsp;Renshan Ge,&nbsp;Haixiao Chen,&nbsp;Zhenghua Hong,&nbsp;Dun Hong","doi":"10.1007/s10585-023-10219-5","DOIUrl":"https://doi.org/10.1007/s10585-023-10219-5","url":null,"abstract":"<p><p>Lung adenocarcinoma is the most common and aggressive type of lung cancer with the highest incidence of bone metastasis. Epidermal growth factor-like domain multiple 6 (EGFL6) is an exocrine protein, and the expression of EGFL6 is correlated with survival of patient with lung adenocarcinoma. However, the association between EGFL6 expression in lung adenocarcinoma and bone metastasis has not been investigated. In this study, we found that EGFL6 levels in lung adenocarcinoma tissues correlate with bone metastasis and TNM stages in surgical patients. In vitro, overexpression of EGFL6 in lung adenocarcinoma cells promoted their proliferation, migration, and invasion ability compared with control by enhancing EMT process and activating Wnt/β-catenin and PI3K/AKT/mTOR pathways. In the nude mouse model, overexpression of EGFL6 enhanced tumor growth and caused greater bone destruction. Moreover, the exocrine EGFL6 of human lung adenocarcinoma cells increased osteoclast differentiation of bone marrow mononuclear macrophages (BMMs) of mice via the NF-κB and c-Fos/NFATc1 signaling pathways. However, exocrine EGFL6 had no effect on osteoblast differentiation of bone marrow mesenchymal stem cells (BMSCs). In conclusion, high expression of EGFL6 in lung adenocarcinomas is associated with bone metastasis in surgical patients. The underlying mechanism may be the increased metastatic properties of lung adenocarcinoma cells with high EGFL6 level and the enhanced osteoclast differentiation and bone resorption by exocrine EGFL6 from tumors. Therefore, EGFL6 is a potential therapeutic target to reduce the ability of lung adenocarcinomas to grow and metastasize and to preserve bone mass in patients with bone metastases from lung adenocarcinomas.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"40 4","pages":"357-371"},"PeriodicalIF":4.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9797668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信